Tert-Butyl 3-((Dimethylamino)Methylene)-4-Oxopyrrolidine-1-Carboxylate

How Does the Enaminone Intermediate Enable the Annulation of the 7H-Pyrrolo[2,3-d]pyrimidine Pharmacophore of a Commercial JAK1/2 Inhibitor?

Manufacture of the active pharmaceutical ingredient ruxolitinib phosphate under full ICH Q7 GMP directives for drug substance intermediates uses the tert-butyl 3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate building block as the critical supplier-managed starting material, with material traceability governed by 21 CFR Part 211 Subpart E and elemental impurities controlled per ICH Q3D Option 2a limits. The validated batch record prescribes a molar feed ratio of 1.00 equivalent of the pre-dried enaminone (water content <0.05% w/w by Karl Fischer, coulometric, as per Ph. Eur. 2.5.32) to 1.05 equivalents of 4-(1H-pyrazol-4-yl)-1H-pyrrole-2-carboximidamide monohydrochloride. In the downstream manufacturing sequence executed in a 500-L glass-lined, double-jacketed reactor under a nitrogen blanket, the enaminone is dissolved in anhydrous methanol (MeOH, water <50 ppm) at 22°C followed by the addition of 1.8 equivalents of triethylamine. The heterogeneous slurry is heated to 65°C ± 2°C and stirred for approximately 6 hours while an in-line Raman probe (Kaiser RXN2, 785 nm excitation) monitors the disappearance of the enaminone νC=O ester band at 1685 cm⁻¹ and the concomitant rise of the pyrimidine ring vibration at 1580 cm⁻¹. After signal plateau indicating >99% conversion, the reaction mass is concentrated under reduced pressure (150 mbar) in a wiped-film evaporator, solvent-switched into isopropyl acetate, washed with 15% w/v aqueous NaCl to remove triethylamine hydrochloride, and passed through a 0.2 µm inline filter. The organic phase is re-concentrated via a rotary thin-film unit to approximately 25% of the original volume, and n-heptane is added via a metering pump at 40°C to initiate seeded crystallization. The resulting crystalline slurry is cooled to –5°C over 3 hours and filtered on a centrifugal disc filter. The wet cake is dried in a biconical rotary vacuum dryer at 45°C / –0.09 MPa for 8 hours to afford the pyrrolo[2,3-d]pyrimidine intermediate with an HPLC purity ≥99.5 area% (AUC at 254 nm, C18 column, acetonitrile/phosphoric acid 0.1% gradient). This intermediate is subsequently subjected to Boc-deprotection with HCl/dioxane and regioselective sulfonylation to produce ruxolitinib free base; its phosphate salt constitutes the approved dosage form marketed as Jakafi®/Jakavi® for the treatment of intermediate- and high-risk primary myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease.

Pyrazole-4-carboxylate Building Blocks Accessed via Regioselective Cyclocondensation with Arylhydrazines

In the construction of fragment libraries targeting central nervous system chemotypes and soluble epoxide hydrolase (sEH) inhibitors, the tert-butyl enaminone serves as a masked 1,3-dipolarophile equivalent that undergoes regioselective cyclization with substituted phenylhydrazines to afford 1-aryl-1H-pyrazole-4-carboxylic acid tert-butyl esters in a single operation. The process is conducted under occupational hygiene standards aligned with OECD 423 guidance for toxicological hazard assessment upon scale-up. The stoichiometric ratio is fixed at 1.00 equivalent of the enaminone to 1.10 equivalents of the phenylhydrazine hydrochloride derivative, with 0.05 equivalents of glacial acetic acid introduced as an acid catalyst to promote imine/amine tautomer equilibrium. Large-scale execution employs a 100-L glass-lined reactor charged with enaminone dissolved in 5 volumes (L/kg) of absolute ethanol; the arylhydrazine salt is fed in 4 equal portions at 25°C to moderate the initial exotherm, and the suspension is then heated to gentle reflux (78°C) and maintained for 4.5 hours with Dean–Stark removal of any incidental moisture. Reaction progress is monitored by TLC (silica gel 60 F254, mobile phase n-hexane:ethyl acetate = 1:1, detection at 254 nm). Once the enaminone spot is absent, the mixture is cooled to –5°C and aged for 2 hours to complete crystallization; centrifugal filtration in a Hastelloy centrifuge yields a wet cake that is washed with chilled (0°C) ethanol and subsequently dried in a fluidized-bed dryer with a hot air stream at 50°C until loss on drying is below 0.5%. The resulting pyrazole-4-carboxylate tertiary-butyl ester is globally deprotected using trifluoroacetic acid in dichloromethane (1:1 v/v) and coupled to aliphatic or aromatic amines via HATU/DIPEA-mediated amidation. Compounds derived from this intermediate have been profiled as negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5) and as potent sEH inhibitors, demonstrating IC₅₀ values in the low-nanomolar range in exploratory studies; selected chemotypes progressed through preliminary non-GLP toxicity assessment before structure-activity refinement.

Directed toward the pilot-scale preparation of a selective human immunodeficiency virus type 1 (HIV-1) capsid assembly modulator that completed Phase IIa clinical evaluation under an exploratory IND, the dimethylaminomethylene-pyrrolidinone intermediate is deployed as a latent 4-oxopyrrolidine-3-carboxylic acid equivalent for diastereoselective reductive amination with a chiral a-methylbenzylamine derivative. Regulatory oversight for this GMP intermediate is defined by ICH Q11 (Development and Manufacture of Drug Substances) Section 5.1.1, where the enaminone is justified as the registered starting material, and analytical characterization must adhere to ICH Q2(R2) validation parameters and ICH M7(R2) for mutagenic impurities, with purge factor calculations documented in the developmental report. The charging stoichiometry requires 1.00 equivalent of the enaminone (dried to a water content ≤0.03% w/w by loss-on-drying halogen balance) to 1.20 equivalents of (R)-1-(4-methoxyphenyl)ethan-1-amine, combined with 1.50 equivalents of sodium triacetoxyborohydride (NaBH(OAc)₃) as the reducing agent. The downstream process in a 50-L Hastelloy C-276 reactor consists of dissolving the enaminone in anhydrous tetrahydrofuran (THF, distilled from sodium/benzophenone) under a dry argon atmosphere and cooling the solution to –10°C ± 3°C using a jacketed temperature control unit circulating silicone oil. The chiral amine is introduced in a single portion, followed by portionwise addition of NaBH(OAc)₃ over 30 minutes while maintaining internal temperature <–5°C. After stirring at –10°C for 1 hour and warming to 22°C overnight (15 hours), the reaction mixture is quenched into a 10% w/v aqueous NaHCO₃ solution at 0°C, filtered through a celite pad, and extracted with methyl tert-butyl ether (MTBE, 3 × 8 L). The combined organic layer is dried over anhydrous Na₂SO₄, filtered, and evaporated to a viscous oil. Purification by normal-phase flash chromatography on silica gel 60 (column length-to-diameter ratio 12:1, eluent n-heptane:ethyl acetate = 3:2) yields the single diastereomer with chemical purity ≥99.0% (HPLC, 215 nm) and individual unspecified impurities <0.10%. Following hydrogenolytic debenzylation and cyclopropanesulfonamide coupling under Schotten–Baumann conditions, the terminal drug candidate—sharing pharmacophore features with the class of HIV-1 capsid inhibitors represented by lenacapavir—was advanced to long-acting injectable formulation development.

When Hydrazine Cyclization Is Executed at a 200-L Pilot Scale: Adiabatic Calorimetry Constraints and Semi-Batch Feeding Strategy

Process safety evaluation for the condensation of the tert-butyl enaminone with 80% aqueous hydrazine hydrate to manufacture 1H-pyrazole-4-carboxylic acid tert-butyl ester—a downstream synthon needed for a marketed oral soluble guanylate cyclase (sGC) stimulator approved by the EMA under EU/1/13/881—reveals a highly exothermic event with concomitant non-condensable gas generation above certain critical temperatures. The hazard assessment conducted in accordance with ASTM E1981-22 and using an accelerating rate calorimeter (ARC 254, NETZSCH) demonstrates an onset temperature of 94°C for the main cyclization exotherm and a calculated adiabatic temperature rise (ΔT_ad) of 98 K, resulting in a potential maximum temperature of synthesis reaction (MTSR) exceeding 190°C in the event of thermal runaway. At temperatures above 120°C, a secondary decomposition autocatalyzed by liberated dimethylamine is observed with a pressure rate exceeding 1.5 bar/min; vent sizing calculations based on DIERS methodology mandate a 4-inch (DN100) rupture disc in the headspace of the production vessel. Accordingly, the competent authority-required ICH Q10 quality risk management file stipulates a strict semi-batch controlled-addition protocol. In the manufacturing procedure, the enaminone is dissolved in 2-methyltetrahydrofuran (2-MeTHF, stabilized with 250 ppm BHT) at a concentration of 0.8 M, and 1.05 equivalents of hydrazine hydrate (80% w/w, N₂H₄ content verified by iodate titration) are metered into the reactor via a PTFE diaphragm metering pump at a constant rate over 4 hours while the jacket cooling system maintains an internal temperature <30°C. The processing equipment comprises a 200-L glass-lined jacket reactor equipped with a retreat-curve impeller and an external plate heat exchanger (cooling surface area 6 m²). After the feed is completed, the reaction mixture is held at 25°C until in-situ ReactIR (Mettler-Toledo) confirms the disappearance of the enaminone C=O signal, typically an additional 1 hour. The mass is washed with water to remove excess hydrazine, and the organic phase is concentrated under vacuum at 35°C to initiate nucleation. Solvent displacement with n-heptane is performed in three stages to reduce residual 2-MeTHF to <200 ppm by headspace GC-FID. The crystalline product is collected by centrifugal filtration, and the wet cake is dried in a biconical rotary dryer at 55°C / –0.09 MPa for 12 hours, affording the N-Boc-pyrazole-4-carboxylic acid as an off-white crystalline solid with HPLC purity 99.2% (AUC) and a consistent particle size distribution (D₉₀ 120 µm). This key intermediate is subsequently activated as the mixed anhydride and coupled with a tetrahydrofuran-propanamine fragment in the regulated sequence to deliver the terminal sGC stimulator API tablets for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Processing of pyrazole-4-carbonyl chlorides for optimised succinate dehydrogenase inhibitor (SDHI) fungicide backbones at the pre-development kilogram scale starts from the enaminone as an inexpensive difunctionalized pyrrolidinone, thereby bypassing earlier linear routes requiring cryogenic lithiation or carbon monoxide high-pressure insertion. The intermediate is produced under a site quality system certified to ISO 14001:2015 for environmental management, with the discharged aqueous waste achieving 68% biodegradation in 28 days per OECD 301F respirometric measurement. In a typical cyclocondensation-batch process executed in a 50-L polypropylene stirred vessel, the enaminone and methylhydrazine (40% aqueous solution) are charged in a molar ratio of 1.00:1.20 and allowed to react at 20 ± 5°C for 2 hours with no external heating; the intermediate pyrazole ester is extracted into dichloromethane, dried over Na₂SO₄, and concentrated under reduced pressure to a viscous oil that is directly subjected to ester hydrolysis with 4 N NaOH at 60°C for 3 hours. Following acidification, the free pyrazole-4-carboxylic acid is isolated by filtration and treated with oxalyl chloride (1.5 equivalents) in dichloromethane with catalytic DMF (0.02 equivalents) to generate the labile pyrazole-4-carbonyl chloride as a 0.5 M stock solution. This activated species is immediately combined with various aryl-2-amino-3-methylbutyramide derivatives in parallel library synthesis to deliver a series of lead amides, several of which were subsequently optimized and advanced through field trials to yield the broad-spectrum SDHI fungicide classes represented by commercial active substances fluxapyroxad and pydiflumetofen, registered for control of Septoria tritici, Pyrenophora teres, and Fusarium head blight in cereal cropping systems.